Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers

Ashley Hopkins, Andrew Rowland, Ganessan Kichenadasse, Michael Wiese, Howard Gurney, Ross McKinnon, Christos Karapetis, Michael Sorich

    Research output: Contribution to journalArticle

    68 Citations (Scopus)

    Abstract

    Immune checkpoint inhibitors (ICI) are an important development in the treatment of advanced cancer. A substantial proportion of patients treated with ICI do not respond, and additionally patients discontinue treatment due to adverse effects. While many novel biological markers related to the specific mechanisms of ICI actions have been investigated, there has also been considerable research to identify routinely available blood and clinical markers that may predict response to ICI therapy. If validated, these markers have the advantage of being easily integrated into clinical use for nominal expense. Several markers have shown promise, including baseline and post-treatment changes in leucocyte counts, lactate dehydrogenase and C-reactive protein. While promising, the results between studies have been inconsistent due to small sample sizes, follow-up time and variability in the assessed markers. To date, research on routinely available blood and clinical markers has focussed primarily on ICI use in melanoma, the use of ipilimumab and on univariate associations, but preliminary evidence is emerging for other cancer types, other ICIs and for combining markers in multivariable clinical prediction models.

    Original languageEnglish
    Pages (from-to)913-920
    Number of pages8
    JournalBritish Journal of Cancer
    Volume117
    Issue number7
    Early online date2017
    DOIs
    Publication statusPublished - 2017

    Fingerprint Dive into the research topics of 'Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers'. Together they form a unique fingerprint.

  • Cite this